HbA1c -0.91% (n=79) vs -0.96% (n=76) Alogliptin @ 12wk25 mg QD + 0.2 mg TID
absolute change · percentage points
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
show 9 more results
-0.21% (n=79) vs -0.19% (n=76) Alogliptin @ 2wk25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
-0.43% (n=79) vs -0.44% (n=76) Alogliptin @ 4wk25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
-0.75% (n=79) vs -0.74% (n=76) Alogliptin @ 8wk25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
-0.6982% (n=156) vs -0.9335% (n=156) Acarbose @ 12wk0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
-0.4765% (n=156) vs -0.631% (n=156) Acarbose @ 6wk0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
0.04% (n=74) vs -0.96% (n=76) Alogliptin @ 12wk0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
-0.01% (n=74) vs -0.19% (n=76) Alogliptin @ 2wk0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
-0.02% (n=74) vs -0.44% (n=76) Alogliptin @ 4wk0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
-0.01% (n=74) vs -0.74% (n=76) Alogliptin @ 8wk0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
Fasting Glucose -0.4234 vs -0.8851 Acarbose mmol/L @ 6wk0.2 mg
absolute change · mmol/L
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-0.5041 vs -0.8029 Acarbose mmol/L @ 12wk0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
Fasting Insulin 0.0319 vs 2.4169 Acarbose μU/dL @ 12wk0.2 mg
absolute change · μU/dL
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
HOMA IR -0.366 vs 0.4983 Acarbose Insulin resistance @ 12wk0.2 mg
absolute change · Insulin resistance
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
HOMA-B 15.3149% (n=156) vs 28.1739% (n=156) Acarbose @ 12wk0.2 mg
absolute change · percentage points
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
Weight -0.016 vs -0.1731 Acarbose kg @ 2wk0.2 mg
absolute change · kg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
-0.6315 vs -0.7975 Acarbose kg @ 6wk0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
-1.1563 vs -1.4394 Acarbose kg @ 12wk0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
HbA1c -0.79% (n=100) @ 8wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
absolute change · percentage points
No placebo or comparator arm
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
show 25 more results
-0.96% (n=99) @ 12wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.96% (n=84) @ 16wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.89% (n=83) @ 20wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.88% (n=82) @ 24wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.89% (n=82) @ 28wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.85% (n=82) @ 32wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.9% (n=78) @ 36wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.92% (n=78) @ 40wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.94% (n=51) @ 44wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.94% (n=49) @ 48wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.95% (n=48) @ 52wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.89% (n=105)Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.69% (n=107) @ 8wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.89% (n=106) @ 12wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.91% (n=91) @ 16wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.9% (n=90) @ 20wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.83% (n=90) @ 24wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.81% (n=88) @ 28wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.8% (n=86) @ 32wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.82% (n=84) @ 36wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.78% (n=82) @ 40wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.88% (n=53) @ 44wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.92% (n=53) @ 48wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.95% (n=53) @ 52wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.81% (n=108)Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
Fasting Plasma Glucose -1.13 mmol/L @ 8wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
absolute change · mmol/L
No placebo or comparator arm
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -20.4 mg/dL as posted
show 25 more results
-1.04 mmol/L @ 12wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.8 mg/dL as posted
-0.85 mmol/L @ 16wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.3 mg/dL as posted
-0.83 mmol/L @ 20wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15 mg/dL as posted
-0.87 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.6 mg/dL as posted
-1.22 mmol/L @ 28wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -21.9 mg/dL as posted
-1.12 mmol/L @ 32wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -20.1 mg/dL as posted
-1.25 mmol/L @ 36wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -22.6 mg/dL as posted
-1.27 mmol/L @ 40wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -22.8 mg/dL as posted
-1.35 mmol/L @ 44wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -24.4 mg/dL as posted
-1.28 mmol/L @ 48wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -23.1 mg/dL as posted
-1.33 mmol/L @ 52wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -24 mg/dL as posted
-1.29 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -23.3 mg/dL as posted
-1.01 mmol/L @ 8wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.2 mg/dL as posted
-0.95 mmol/L @ 12wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.1 mg/dL as posted
-0.89 mmol/L @ 16wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -16 mg/dL as posted
-0.87 mmol/L @ 20wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.6 mg/dL as posted
-0.77 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -13.8 mg/dL as posted
-0.8 mmol/L @ 28wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -14.5 mg/dL as posted
-0.98 mmol/L @ 32wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.7 mg/dL as posted
-0.96 mmol/L @ 36wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.3 mg/dL as posted
-1.09 mmol/L @ 40wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -19.7 mg/dL as posted
-1.19 mmol/L @ 44wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -21.5 mg/dL as posted
-1.14 mmol/L @ 48wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -20.5 mg/dL as posted
-1.15 mmol/L @ 52wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -20.7 mg/dL as posted
-0.97 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.5 mg/dL as posted
PPG 2h Change mg/dL 2.09 mmol/L @ 12wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
absolute change · mmol/L
No placebo or comparator arm
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 37.6 mg/dL as posted
show 7 more results
2.06 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 37.1 mg/dL as posted
2.26 mmol/L @ 52wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 40.8 mg/dL as posted
2.19 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 39.4 mg/dL as posted
2.29 mmol/L @ 12wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 41.2 mg/dL as posted
2.11 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 38 mg/dL as posted
2.16 mmol/L @ 52wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 39 mg/dL as posted
2.2 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 39.6 mg/dL as posted
PPG AUC Change Mgmin dL -76.8 mg @ 12wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
absolute change · mg
No placebo or comparator arm
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
show 7 more results
-70.4 mg @ 24wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-83.4 mg @ 52wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-82.2 mgAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-73.2 mg @ 12wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-69 mg @ 24wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-83.5 mg @ 52wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-77.5 mgAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
Fasting Plasma Glucose -1.04 vs -0.86 Alogliptin mmol/L @ 2wk25 mg QD + 0.2 mg TID
absolute change · mmol/L
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.8 mg/dL as posted
show 7 more results
-1.25 vs -0.9 Alogliptin mmol/L @ 4wk*25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -22.6 mg/dL as posted
-1.22 vs -1.15 Alogliptin mmol/L @ 8wk*25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -21.9 mg/dL as posted
-1.03 vs -1.06 Alogliptin mmol/L @ 12wk*25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.5 mg/dL as posted
-0.19 vs -0.86 Alogliptin mmol/L @ 2wk*0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -3.5 mg/dL as posted
-0.03 vs -0.9 Alogliptin mmol/L @ 4wk*0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -0.6 mg/dL as posted
-0.14 vs -1.15 Alogliptin mmol/L @ 8wk*0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -2.5 mg/dL as posted
-0.31 vs -1.06 Alogliptin mmol/L @ 12wk*0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -5.6 mg/dL as posted
PPG 2h Change mg/dL 2.15 vs 2.27 Alogliptin mmol/L @ 12wk25 mg QD + 0.2 mg TID
absolute change · mmol/L
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 38.7 mg/dL as posted
show 1 more result
4.02 vs 2.27 Alogliptin mmol/L @ 12wk*0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from 72.4 mg/dL as posted
+ 1 further endpoint in the CSV export.